Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    92
    ...
ATC Name B/G Ingredients Dosage Form Price
B05CX01 DEXTROSE G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 185,340 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C10AA05 TARDEN G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,055,876 L.L
D08AX02 EOSIN ALCOHOLIC G Eosin - 1% 1% Solution 108,787 L.L
J01CR05 YANOVEN G Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g Injectable powder for solution 997,259 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 2.5mg 2.5mg Tablet 52,290,378 L.L
M01AE03 KETOPROFENE MACOPHARMA G Ketoprofen - 100mg/100ml 100mg/100ml Injectable solution 329,241 L.L
N06AB10 CITOLES G Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 511,940 L.L
R03AC02 BUTALIN G Salbutamol (sulfate) - 100mcg/dose 100mcg/dose Inhalation aerosol metered dose 145,135 L.L
R06AX27 DELINE G Desloratadine - 5mg 5mg Tablet 149,742 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 5,916,747 L.L
B05CX01 DEXTROSE 5% INJECTION USP G Glucose - 5% 5% Injectable solution 158,587 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 25mg 25mg Tablet, coated 1,849,127 L.L
C09CA04 ANDARAN G Irbesartan - 150mg 150mg Tablet, film coated 904,612 L.L
C10AA05 TORVACOL 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, coated 2,363,819 L.L
D08AX02 EOSIN AQUEUSE G Eosin - 1% 1% Solution 84,470 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 5mg 5mg Tablet 1,635,456 L.L
J01CR05 YANOVEN G Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g Injectable powder for solution 10,860,623 L.L
J01MA12 EVOXIL HELLAS G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 959,504 L.L
M01AE03 SOLKET G Ketoprofen Lysine salt - 80mg 80mg Powder for solution 636,981 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 1,410,395 L.L
R03AC02 BUTO-ASMA G Salbutamol - 100mcg 100mcg Inhalation 237,860 L.L
R06AX27 DELINE-MED G Desloratadine - 5mg 5mg Tablet 566,974 L.L
A02BC01 OMEPRAL G Omeprazole - 20mg 20mg Powder for suspension 712,876 L.L
B05CX01 DEXTROSE 5% INJECTION USP G Glucose - 5% 5% Injectable solution 171,228 L.L
C03DA04 HEPERONA 25 G Eplerenone - 25mg 25mg Tablet, coated 2,116,552 L.L
C09CA04 CONVERIUM G Irbesartan - 150mg 150mg Tablet 585,915 L.L
C10AA05 TORVALIP 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,164,664 L.L
D10AD01 A-RET G Tretinoin - 0.05% 0.05% Cream 335,961 L.L
G04BE08 DURALIS 5 G Tadalafil - 5mg 5mg Tablet, film coated 1,791,790 L.L
    ...
    92
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025